Laurence Albiges, MD, PhD

Articles

Managing AEs in Cabo Nivo Combination Therapy for Advanced RCC

December 5th 2023

Expert oncologists discuss the nuances of managing toxicities associated with Cabozantinib and Nivolumab combination therapy for advanced renal cell carcinoma (RCC).

Sequencing and Second-Line Therapy in RCC: Patient Scenario

December 5th 2023

Expert oncologists discuss the challenges and considerations in choosing second-line therapy for a patient with metastatic renal cell carcinoma (RCC) in a case-based context.

Key Decision Factors in Selecting Frontline Therapy for Metastatic RCC

November 28th 2023

Renowned oncologists discuss critical factors influencing their decisions for frontline therapy in metastatic renal cell carcinoma (RCC), including risk assessment, sites of metastasis, performance status, and treatment goals.

Comparing Treatment Combinations in Renal Cell Carcinoma

November 28th 2023

A comprehensive discussion on VEGF-TKI-based combinations and immune checkpoint inhibitor combinations in the treatment of renal cell carcinoma, featuring key clinical trial results and treatment strategies.

Treatment Strategies for Non-Clear Cell Renal Cell Carcinoma

November 21st 2023

Expert panelists review the management of non-clear cell histology in renal cell carcinoma, exploring treatment options, clinical trials, and the potential role of immune checkpoint inhibitors.

Frontline Therapy for Renal Cell Carcinoma: Choosing the Right Regimen

November 21st 2023

Oncologists discuss the selection of the optimal frontline therapy for renal cell carcinoma, considering factors like response rates, progression, quality of life, and long-term results.

Imaging and Staging Considerations in Renal Cell Carcinoma

November 14th 2023

Key opinion leaders discuss the use of brain MRI and bone assessment in the staging and monitoring of patients with renal cell carcinoma.

Frontline Therapy for Advanced Renal Cell Carcinoma: Patient Scenario Discussion

November 14th 2023

Renowned oncologists discuss the case of a 75-year-old man with advanced renal cell carcinoma, providing insights into evaluation and frontline therapy choices.

Overview on Advanced RCC: Epidemiology, Presentation, and Risk Stratification

October 30th 2023

Explore statistics behind and possible patient presentations of advanced renal cell carcinoma (RCC), with insight into IMDC risk stratification that may influence treatment strategies and outcomes.

Dr. Albigès on the CaboPoint Trial in Advanced RCC

February 18th 2023

Laurence Albigès, MD, PhD, discusses the main objective and trial design of the phase 2 CaboPoint study in renal cell carcinoma, as well as key efficacy and safety data reported in an interim analysis of this study.